Last $61.06 USD
Change Today -1.56 / -2.49%
Volume 5.5M
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 8:04 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
$61.97
Previous Close
$62.62
Day High
$62.45
Day Low
$60.94
52 Week High
07/24/14 - $65.70
52 Week Low
10/8/13 - $47.53
Market Cap
68.2B
Average Volume 10 Days
4.2M
EPS TTM
$3.22
Shares Outstanding
1.1B
EX-Date
08/13/14
P/E TM
19.0x
Dividend
$1.96
Dividend Yield
3.21%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Eli Lilly and Company Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Financial Guidance for the Full Year of 2014

Eli Lilly and Company reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net income of $733.5 million or $0.68 per diluted share on total revenue of $4,935.6 million against net income of $1,206.2 million or $1.11 per diluted share on total revenue of $5,929.7 million a year ago. On Non-GAAP basis, net income of $733.5 million or $0.68 per diluted share on total revenue of $4,935.6 million against net income of $1,254.9 million or $1.16 per diluted share on total revenue of $5,929.7 million a year ago. The revenue decrease was due to a 17% decline in volume; the impact of changes in price and foreign exchange rates on worldwide revenue was negligible. The decreases in net income and earnings per share were driven primarily by lower operating income. For the six months, the company reported net income of $1,461.4 million or $1.36 per diluted share on total revenue of $9,618.7 million against net income of $2,754.2 million or $2.53 per diluted share on total revenue of $11,531.7 million a year ago. On Non-GAAP basis, net income of $1,483.4 million or $1.38 per diluted share on total revenue of $9,618.7 million against net income of $2,502.6 million or $2.30 per diluted share on total revenue of $11,531.7 million a year ago. The company has revised certain elements of its 2014 financial guidance. Full-year 2014 earnings per share are now expected to be in the range of $2.67 to $2.75 on a reported basis. On a non-GAAP basis, full-year earnings per share are still expected to be in the range of $2.72 to $2.80. The company still anticipates revenue of between $19.4 billion and $20.0 billion. Patent expirations have driven a rapid and severe decline in U.S. Cymbalta and U.S. Evista sales. These revenue declines are expected to be partially offset by growth from a portfolio of other current products including Humalog, Trajenta(R), Cialis, Forteo and Alimta, as well as the animal health business and new product launches. In addition, strong revenue growth is expected in China, while a weaker Japanese yen will dampen revenue growth in Japan. The company still anticipates that gross margin as a percent of revenue will be approximately 73% in 2014. The tax rate is still expected to be approximately 19%, assuming a full-year 2014 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the 2014 tax rate would be approximately 2 percentage points higher. The company still expects net income to be at least $2.9 billion and still expects operating cash flow to be at least $4.0 billion. Operating cash flows are still expected to be sufficient to pay the company's dividend of approximately $2.1 billion, allow for capital expenditures that are now expected to be approximately $1.2 billion, and fund certain business development activity and share repurchases.

Eli Lilly and Company Seeks Acquisitions

Eli Lilly and Company (NYSE:LLY) is seeking acquisitions. Sue Mahony, President, Lilly Oncology, Eli Lilly and Company, said, "We're also continuing to increase our discovery efforts and capabilities, both internally and through recruitment externally in this area, and we've got a number of targets that we're interested in, in addition to collaborations and partnerships and potential acquisitions that we're looking at."

Eli Lilly Announces to Cut 100 Jobs, Move Work Overseas

Eli Lilly and Co. announced that will send some drug production overseas and cut up to 100 Indianapolis jobs under a plan to "rebalance" its tablet and capsule manufacturing business. The expiration of patents on several Lilly drugs, which sent their sales plummeting, is part of the reason for the restructuring. As many as 100 positions will be affected by the moves. Employees in those jobs will be offered other jobs locally, including in the insulin and other biotech product lines. Lilly has committed to spending nearly $500 million on insulin facilities in Indianapolis, including cartridge-filling plants for the pen injection devices diabetics use.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $61.06 USD -1.56

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.12 USD -0.74
AbbVie Inc $52.34 USD -1.41
Amgen Inc $127.39 USD -2.62
Bristol-Myers Squibb Co $50.62 USD -0.50
Teva Pharmaceutical Industries Ltd $53.50 USD -1.38
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 19.9x
Price/Sales 3.2x
Price/Book 3.7x
Price/Cash Flow 20.6x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.